Alembic Pharmaceuticals Ltd (APLLTD)
₹799.55
Mkt cap
₹15,886 Cr
P/E ratio
21.30
P/B
2.77
Div yield
1.48%
ROE
13.40%
ROCE
12.60%
EPS (TTM)
₹37.54
Book value
₹289
52W range
647–978
Sector
Healthcare
Price history
Previous close
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
NSE APLLTDBSE 533573
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−18.25% from high₹800
₹647+23.66% from low₹978
Current
₹799.55
Prev close
₹808.20
Day
−1.07%
Price performance
1D
−0.65%
1W
−3.83%
1M
−3.27%
3M
+9.77%
6M
+14.99%
1Y
−14.82%
YTD
−4.25%
Financials
Revenue, profit & margin
P/E ratio
21.3×
APLLTD is 37% below the sector median of 34.0×
APLLTD21.3×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 | |
| Expenses | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 | |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 | |
| OPM % | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% | |
| Other Income | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 | |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 | |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 | |
| Profit before tax | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 | |
| Tax % | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% | |
| Net Profit | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 | |
| EPS in Rs | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.99% · closed higher next day 17 of last 57
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 5 Feb '24◦ | 9 May '24◦ | 8 Aug '24◦ | 7 Nov '24◦ | 3 Feb '25◦ | 6 May '25 | 5 Aug '25◦ | 4 Nov '25 | 5 Feb '26 | 15 May '26 | 4 Aug '26 |
| Earnings day | −0.97% | +2.15% | −2.57% | −6.89% | −3.86% | −2.88% | +1.13% | +0.18% | +3.95% | +1.52% | −0.20% | +0.45% |
| +1 day | −0.78% | +1.23% | −4.80% | −8.50% | −4.43% | −2.06% | +1.73% | +0.41% | −0.96% | −0.09% | −7.80% | +1.55% |
| +5 days | +0.65% | +2.95% | −4.14% | −11.78% | −5.12% | −4.35% | +2.35% | −0.40% | −0.82% | −1.06% | −3.82% | +4.11% |
| +15 days | +1.51% | +8.83% | −7.81% | −11.87% | +1.80% | −12.73% | +11.52% | −1.01% | −1.02% | −8.61% | −5.12% | −0.33% |
| +30 days | +4.49% | −2.04% | −9.87% | −4.02% | −4.12% | −8.00% | +8.12% | +1.32% | −8.34% | −15.16% | +4.72% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 12 Per Share | 12.00 | 29 Jul '26 | 29 Jul '26 |
Shareholding
as of Jun 202669.87%Promoter
Promoters69.87%0.13
FIIs4.17%0.09
DIIs15.93%0.24
Public10.00%0.17
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| APLLTD | ₹808.20 | 21.29 | 15,886 | 1.48% | 172 | +12.11% | 2,150 | +25.66% | 12.64% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts64
PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 AugAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Aug - Alembic Pharmaceuticals scheduled one-to-one investor meetings on September 1-2, 2026 in Mumbai and virtually.Announcement under Regulation 30 (LODR)-Newspaper Publication 25 AugAppointment of Company Secretary and Compliance Officer 20 Aug - Mr. Chirag Shukla appointed Company Secretary and Compliance Officer effective 20 August 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 11 Aug